Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?

Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?

Since the 1950s, there have been concerns about the definition of response in solid tumors and the reliance on quantitative measurements. Gehan and Tefft discuss new guidelines for evaluating response, referred to as RECIST (Response Evaluation Criteria in Solid Tumors), and how they differ from cri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 2000-02, Vol.92 (3), p.179-181
Hauptverfasser: Gehan, Edmund A., Tefft, Mariella C.
Format: Artikel
Sprache:eng
Schlagworte:
Antineoplastic Agents - therapeutic use
Cancer
Clinical Trials as Topic - methods
Clinical Trials as Topic - standards
Dose-Response Relationship, Drug
Editorials
Guidelines
Humans
Neoplasms - drug therapy
Outcome Assessment (Health Care) - methods
Outcome Assessment (Health Care) - standards
Research Design
Treatment Outcome
Tumors
United States
World Health Organization
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Since the 1950s, there have been concerns about the definition of response in solid tumors and the reliance on quantitative measurements. Gehan and Tefft discuss new guidelines for evaluating response, referred to as RECIST (Response Evaluation Criteria in Solid Tumors), and how they differ from criteria set up by the World Health Organization (WHO).
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/92.3.179